Compare TFPM & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFPM | MMED |
|---|---|---|
| Founded | 2016 | 1983 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.5B |
| IPO Year | 2022 | 2025 |
| Metric | TFPM | MMED |
|---|---|---|
| Price | $30.62 | $19.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $39.50 | $24.69 |
| AVG Volume (30 Days) | 372.8K | ★ 4.1M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $3,102,000,000.00 |
| Revenue This Year | $26.18 | $10.81 |
| Revenue Next Year | $11.37 | $8.28 |
| P/E Ratio | $35.57 | ★ N/A |
| Revenue Growth | N/A | ★ 14.25 |
| 52 Week Low | $26.61 | $10.65 |
| 52 Week High | $41.70 | $24.43 |
| Indicator | TFPM | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 42.37 |
| Support Level | $26.81 | $10.68 |
| Resistance Level | $32.02 | $20.88 |
| Average True Range (ATR) | 0.76 | 0.76 |
| MACD | -0.24 | -0.26 |
| Stochastic Oscillator | 21.52 | 17.88 |
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.